Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 20 Sep 2019 Planned primary completion date changed from 31 Aug 2019 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated
- 20 Aug 2018 Status changed from recruiting to active, no longer recruiting.